Rallybio Corporaton RLYB

$17.08 +0.32 (1.91%)

Valuation

Market cap
89,004,000
Revenue TTM
$860,000
Net income TTM
$-8,980,000
PE ratio
0.00
Forward PE
—
Profit margin
-1,044.19%
Debt to equity
0.00

Trading

Volume
7,800
Avg volume
15,072
Day's range
$16.69 – $17.22
Shares out
5,311,000
Stochastic %K
77%
Beta
-0.72
Analysts
Hold
Price target
$8.00

Price

Company profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the tre...

Show more

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Phone
203 859 3820
Website
https://www.rallybio.com
Address
234 Church Street, New Haven, United States

Latest news

Stocktwits

SqueezeSpecs Sep 27, 10:47 AM
$RLYB: Rallybio is moving toward its planned merger with Avenzo Therapeutics, which would create an oncology-focused publicly traded biotech. Rallybio shareholders are expected to own about 2.8% of the combined company under the current filing. ("rallybio(dot)com" (https://investors.rallybio.com/news-releases) ) RLYB closed Friday at $16.62, essentially flat on the day. The company also reported a $50M termination fee from the previously proposed Candid Therapeutics transaction, adding to its cash resources ahead of the Avenzo merger.
0 replies
CamelMoneyMaker Sep 2, 1:24 AM
I rarely trade penny stocks but $FBIO $FMFC $RLYB these tickers passed the “Graham-NCAV test” Worth keeping them on your watchlist
0 replies
Toni1976 Aug 14, 3:37 AM
$RLYB I’m bullish on RLYB here. The company has demonstrated encouraging clinical data for RLYB116, and the upcoming Avenzo transaction brings a $215M financing and a pipeline of four clinical-stage oncology programs. With the stock still at a relatively small market cap, I see significant asymmetric upside if the transaction closes and the pipeline delivers. High risk, but the potential reward makes RLYB very attractive at these levels
0 replies
Toni1976 Aug 10, 2:33 PM
$RLYB I’m bullish on RLYB because of the strong clinical potential, meaningful unmet need, and the possibility of significant value creation if the upcoming catalysts deliver. The risk is high, but so is the upside.
0 replies
MikeyMcDermott Jun 21, 8:54 PM
OH LOOK -- LONGWOOD FUND PORTFOLIO CO AVENZO THERAPEUTICS REVERSE MERGING WITH $RLYB ANNOUNCED JUNE 1, 2026 WE THINK IMMUNITAS THERAPEUTICS IS LOOKING TO GO PUBLIC VIA REVERSE MERGER WITH $SPRO CASH SHELL AS WELL CONCURRENTLY WITH SELLING TEBI RIGHTS FOR 600 MILLION? IMMUNITAS FOUNDED BY LONGWOOD IN 2019 NEED CASH FOR THAT P3 IMT-009 TRIAL? IMMUNITAS CSO AN "ADVISOR" TO SPERO SINCE JANUARY 2026 SNAP TO IT $GSK https://www.bamsec.com/filing/119312526249790?cik=1739410
1 replies
STOCKGOD47 Jun 2, 7:35 PM
$RLYB speculative
0 replies
MikeyMcDermott Jun 2, 12:30 PM
$FULC this thing was set up to begin reverse merge process in April. CFO announces his resignation April 23. Josh Lehrer appointed as a Board member on April 27. Josh Lehrer was CEO of Gossamer Bio who led the reverse merge into Lenz Therapeutics in 2023 after Gossamer pipeline blew up. I'm not sure when, but FULC will be reverse merge shell for a new private biotech to go public. FULC only had 55 employees as of 12/31 and burned $22 million Q1. My guess is they take burn rate down to $6-$8 million per quarter while looking for reverse merge target. They are in Cambridge MA so should have big network of private biotechs that could use their listing. After severance/cash burn, maybe $250 million is good net cash balance to think about for Exchange Ratio. Might not need a PIPE to go along with any deal. $RLYB just announced reverse merge partner (actually second one after Candid Therapeutics decided to be acquired for $2.2 billion)
2 replies
mikesterz7 Jun 1, 7:05 PM
$RLYB Rallybio announced a merger agreement with Avenzo Therapeutics to create a publicly traded, oncology-focused biotechnology company.
0 replies